Price to sales

RECENT NEWS
AlphaNinja  Nov 18  Comment 
With the earnings picture for 2009 and 2010 changing by the day, it's useful to take a look at Price-to-Sales as a measure of valuation. It doesn't have nearly the same volatility that Price-to-Earnings does. The below chart shows each...
PR Newswire  Nov 18  Comment 
WASHINGTON, Nov. 18 /PRNewswire-USNewswire/ -- Physicians for Social Responsibility today released a groundbreaking medical report, "Coal's Assault on Human Health," which takes a new look at the devastating impacts of coal on the human body. By
PR Newswire  Nov 16  Comment 
American Lung Association, American Nurses Association to Join PSR at November 18 Press Conference WASHINGTON, Nov. 16 /PRNewswire-USNewswire/ -- Physicians for Social Responsibility (PSR) is preparing to release a groundbreaking medical report,
Cheap Stocks  Nov 11  Comment 
We've reviewed 7 years of data, crunched a lot of numbers for JG Boswell, and have been able to string together seven years worth of summarical fundamentals. Due to the complexity, and growing size of our spreadsheet, we've decided to share just...
Motley Fool  Nov 4  Comment 
But should you buy it?
The Globe and Mail  Nov 2  Comment 
Leading industrials and food distributors among Canadian stocks with low PSR
Motley Fool  Aug 26  Comment 
But should you buy it?
Motley Fool  Jul 21  Comment 
But should you buy it?
The Enlightened American  Jul 15  Comment 
Following on my recent post that revealed the rise in American consumption predicated in large part on ever-rising healthcare costs, I decided to question my own view that US consumers would drastically retrench. Contrarian thinking is key to...
Motley Fool  Jul 14  Comment 
They're not always as enticing as they appear.
Suggest a News Source
Topic
Top news source/blog that we're missing
Why do you recommend this news source?
Close 
Thanks for your suggestion!
 
 
TOP CONTRIBUTORS

Price to sales equals a company's share price divided by its per-share sales or revenue.

The price to sales ratio (also known as price to sales, price/sales, P/S or PSR) is a valuation metric that looks at a company's current share price relative to its sales or revenue per share. It is usually calculated by dividing the company's share price by its per-share sales or revenue, although it can also be calculated by dividing the company's market capitalization by its total sales or revenue in the past 12 months. A company trading at low price to sales, especially when compared to other companies in the same industry, is considered to be undervalued relative to its share price.

In general, a company trading at price to sales of less than 1.0 is worthy of note. As an illustration, consider a company that has $1.0 billion in sales, a market capitalization of $900 million and, therefore, a price to sales ratio of 0.9. This means that you can buy $1.0 of the company's sales for just $0.9. While this could point to an overlooked bargain, the low share price could also mean that there's something else wrong with this company.

P/S Ratio   =     Share Price     =   Market Capitalization   =   P/E Ratio x Profit Margin
                Per-Share Sales            Total Sales

Key Considerations

In the price to sales ratio, the numerator (share price) takes into account a company's leverage, whereas the denominator (per-share sales or revenue) does not. As a result, when comparing price to sales for two companies, the implicit assumption is that both firms have the same capital structure, which often isn't the case. For example, while it's easy to find lots of companies with no profits and huge debt trading at price to sales of 0.3 or less, most of them are probably on the verge of bankruptcy and definitely not bargain stocks.

This assumption becomes more problematic when comparing companies that operate in different industries since capital structures and profit margins vary widely from one industry to another. For example, grocery stores tend to have lower profit margins and earn only a few pennies on every dollar of sales as compared to medical device manufacturers. In other words, relative to the grocer, a medical device maker does not require as much in sales to make a $1.0 in earnings. According to Morningstar, grocers and medical device manufacturers have average price to sales ratios of 0.5 and 5.0 respectively. Hence, a grocer with a price to sales ratio of 2.0 should be viewed as expensive, while a medical device maker with the same price to sales ratio could be a bargain.

In view of the above, price to sales is most useful when comparing companies in the same sector or sub-sector.

P/E vs. P/S

Compared to the P/E ratio, the P/S ratio has the following advantages:

  • Less Volatile: Sales are less volatile than earnings and the P/E ratio cannot be used to evaluate a company that is losing money. In other words, a company with negative earnings, but strong sales, may still be a good long-term investment and will always have a well-defined P/S ratio, but no P/E ratio.
  • Harder to Manipulate: Sales are also harder to manipulate and subject to fewer accounting estimates and one-off events than earnings.

Nonetheless, sales mean very little without earnings. If two companies have the same price to sales ratio, but one has a higher profit margin (i.e. it's earning more money from sales), it is a better investment, all else being equal.

Price to Sales on Wikinvest

Wikinvest calculates Price to Sales as market capitalization divided by trailing twelve month (TTM) revenue. Our number would disagree with that on Yahoo! Finance because Yahoo! uses market capitalization from the day before. Wikinvest, on the other hand, calculates the number in real-time i.e. the number changes during the day as a company's market cap changes.

Please install Flash Player to view this chart.
Please install Flash Player to view this chart.
Wikinvest © 2006, 2007, 2008, 2009. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki